Independent analysts on the Seeking Alpha platform issued a series of rating changes on May 22, covering four key stocks: NVIDIA, Meta Platforms, JPMorgan Chase, and GoodRx Holdings.
NVIDIA: Earnings Beat Drives Analyst Upgrade NVIDIA received a rating upgrade from Cestrian Capital Research. The firm cited NVIDIA's "exceptionally strong" latest quarterly earnings report as the primary reason for the upgrade. The report showed first-quarter revenue reached $81.62 billion, surpassing market expectations of $78.42 billion, with earnings per share of $1.87, also above the expected $1.76. Wall Street's overall outlook on NVIDIA remains optimistic. Evercore ISI maintained its "Outperform" rating on May 21 and significantly raised its price target from $352 to $413. The firm believes NVIDIA's market leadership in artificial intelligence and gaming will continue to support its growth potential. DZ Bank also reiterated its "Buy" rating on the stock. The current Wall Street analyst consensus rating for NVIDIA is "Buy," with 48 analysts giving a Buy rating, 4 a Strong Buy, and only 2 a Hold. The average price target stands at approximately $303.
Meta Platforms: AI-Driven Optimism, Target Points to $1,000 Meta Platforms received a bullish rating from PropNotes, with the analyst suggesting the stock could reach $1,000. The firm noted that while Meta is facing pressure from significant AI-related capital expenditures, the positive impact of AI technology on its advertising business is accelerating. Meta's latest earnings report showed continued growth in first-quarter advertising revenue, with AI-driven ad tools gaining widespread adoption among advertisers. Analysts expect user engagement and ad conversion rates to improve further as AI integration deepens across platforms like Facebook, WhatsApp, and Instagram. Notably, Meta raised its 2026 capital expenditure guidance to a range of $125 billion to $145 billion, primarily for AI infrastructure. While this has raised concerns about near-term profitability, PropNotes believes the long-term value of AI monetization is not yet fully priced in. The current Wall Street consensus rating for Meta is "Buy," with an average price target around $822.6.
GoodRx: Downgraded to Hold Amid Trump Drug Plan Concerns GoodRx Holdings was the only stock to receive a downgrade in this round of rating changes. The SA analyst pointed out that the "Trump Prescription Drug Plan" poses a substantive threat to GoodRx's business model. The plan, aimed at lowering drug prices through government negotiation, directly erodes the "moat" of GoodRx's price comparison platform. GoodRx's first-quarter earnings report showed a 4% year-over-year decline in revenue, with its EBITDA margin compressed to 18.5%. Management expects the downward trend in its traditional business to persist throughout 2026. The SA analyst downgraded GoodRx to "Hold," estimating a discounted cash flow-based value per share of approximately $2.49, close to the current stock price, with scenario analysis indicating more significant downside risks. The current Wall Street consensus rating for GoodRx is "Buy," based on ratings from 10 analysts, with an average price target of $4.78. JPMorgan maintained a "Buy" rating but lowered its price target from $6 to $5, while Jefferies downgraded the stock from "Strong Buy" to "Hold" in January, slashing its target from $5.25 to $2.75.
JPMorgan Chase: Added to Analyst Watchlist JPMorgan Chase received positive attention from the SA analyst in this round. The firm was added to the analyst's watchlist with a rating of "Moderate Buy" and an average price target of $339.08. JPMorgan's first-quarter earnings showed EPS of $5.94, beating expectations, with revenue of $50.54 billion also exceeding market forecasts and growing 10% year-over-year. Analysts currently project full-year EPS of approximately $22.43. The company also announced a quarterly dividend of $1.50 per share, or $6.00 annualized, representing a dividend yield of about 2.0%. On Wall Street, JPMorgan has 15 Buy ratings and 15 Hold ratings, resulting in a consensus rating of "Moderate Buy." Piper Sandler raised its target price from $325 to $345 with an "Overweight" rating, while Daiwa Securities lowered its target from $340 to $328 but maintained an "Outperform" rating.
Comments